Why Is Cytokinetics (CYTK) Down 9.7% Since Last Earnings Report?

Zacks12-07

It has been about a month since the last earnings report for Cytokinetics (CYTK). Shares have lost about 9.7% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2489251670?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0K2vxHTAGj_tGrBqjPJ8Cg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/f889276f4a638f3c7a79c0e3e6b768c1","is_english":true,"pubTime":"2024-12-07 00:31","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2489251670","market":"us","top_or_hot":-1,"title":"Why Is Cytokinetics (CYTK) Down 9.7% Since Last Earnings Report?","media":"Zacks","content":"<div>\n<p>It has been about a month since the last earnings report for Cytokinetics (CYTK). Shares have lost about 9.7% in that time frame, underperforming the S&P 500.\nWill the recent negative trend continue ...</p>\n\n<a href=\"https://finance.yahoo.com/news/why-cytokinetics-cytk-down-9-163115947.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is Cytokinetics (CYTK) Down 9.7% Since Last Earnings Report?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is Cytokinetics (CYTK) Down 9.7% Since Last Earnings Report?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-07 00:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/why-cytokinetics-cytk-down-9-163115947.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It has been about a month since the last earnings report for Cytokinetics (CYTK). Shares have lost about 9.7% in that time frame, underperforming the S&P 500.\nWill the recent negative trend continue ...</p>\n\n<a href=\"https://finance.yahoo.com/news/why-cytokinetics-cytk-down-9-163115947.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INSM","symbol_name":"Insmed","start_time":0,"source_url":"https://finance.yahoo.com/news/why-cytokinetics-cytk-down-9-163115947.html","article_id":"2489251670","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0K2vxHTAGj_tGrBqjPJ8Cg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/f889276f4a638f3c7a79c0e3e6b768c1"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2489251670","pubTimestamp":1733502675,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"It has been about a month since the last earnings report for Cytokinetics . Shares have lost about 9.7% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Cytokinetics due for a breakout?Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.Cytokinetics Q3 Loss Wider Than Expected, Pipeline in Focus. Cytokinetics reported a net loss of $1.36 per share in the third quarter of 2024, wider than the Zacks Consensus Estimate of a loss of $1.27. In the year-ago quarter, the company reported a net loss of $1.35 per share.Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"INSM":"Insmed","CYTK":"Cytokinetics"},"translate_title":"为什么Cytokinetics(CYTK)自上次收益报告以来下跌了9.7%？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CYTK":1,"INSM":0.9},"content_text":"It has been about a month since the last earnings report for Cytokinetics (CYTK). Shares have lost about 9.7% in that time frame, underperforming the S&P 500.\nWill the recent negative trend continue leading up to its next earnings release, or is Cytokinetics due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. \nCytokinetics Q3 Loss Wider Than Expected, Pipeline in Focus\nCytokinetics reported a net loss of $1.36 per share in the third quarter of 2024, wider than the Zacks Consensus Estimate of a loss of $1.27.  In the year-ago quarter, the company reported a net loss of $1.35 per share.\nCytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised.\nSince the company does not have any approved product in its portfolio yet, it does not generate drug sales.  \nTotal revenues for the third quarter were $0.5 million, up from $0.4 million in the year-ago quarter.\nQuarter in Detail\nR&D expenses amounted to $84.6 million, up 2.5% year over year driven by higher personnel related expenses to progress our pipeline partially offset by the completion of clinical trials.\nGeneral and administrative expenses surged 41.2% to $56.7 million, driven by investments toward commercial readiness and personnel related expenses.\nCash Balance Increase\nAs of Sept. 30, 2024, Cytokinetics had approximately $1.3 billion in cash, cash equivalents and investments, down from $1.4 billion as of Jun. 31, 2024.\nDuring the second quarter, Cytokinetics completed a public offering of 11.27 million shares of its common stock, raising approximately $563.2 million in net proceeds.\nIn May 2024, Cytokinetics entered into a strategic funding collaboration (worth $575 million) with Royalty Pharma to support the commercialization of late-stage candidate aficamten and advance the company’s expanding cardiovascular pipeline.\nPipeline Updates\nCytokinetics completed the rolling submission of the new drug application (NDA) for aficamten and submitted the NDA for the treatment of obstructive hypertrophic cardiomyopathy (HCM).\nResults from the phase III SEQUOIA-HCM study in obstructive HCM showed that treatment with aficamten in SEQUOIA-HCM was associated with improvements in cardiac structure and function, heart failure symptoms, cardiac biomarkers, and multiple assessments of clinical significance to cardiologists.\nAdditionally, an analysis from FOREST-HCM, the open label extension clinical study of aficamten in patients with HCM, demonstrated that patients who attempted withdrawal of standard of care medications did not experience negative impacts on the efficacy or safety of aficamten.\nA marketing authorization application for aficamten in the EU is planned for the fourth quarter.\nCorxel (formerly Ji Xing Pharmaceuticals) completed submission of the NDA for aficamten to treat obstructive HCM. The Center for Drug Evaluation of the National Medical Products Administration in China accepted the NDA.\nAficamten is also currently being evaluated in MAPLE-HCM, a phase III study of aficamten as monotherapy compared to metoprolol as monotherapy in patients with obstructive HCM (enrollment completed) and ACACIA-HCM, a phase III study of aficamten in patients with non-obstructive HCM (enrolment ongoing.\nOther studies include CEDAR-HCM, a clinical trial of aficamten in a pediatric population with obstructive HCM. Enrollment is ongoing in CEDAR-HCM.\nOther pipeline candidates include omecamtiv mecarbil, a cardiac muscle activator, in patients with heart failure. Cytokinetics conducted start-up activities for COMET-HF, a confirmatory phase III multi-center, double-blind, randomized, placebo-controlled trial to assess the efficacy and safety of omecamtiv mecarbil in patients with symptomatic heart failure with severely reduced ejection fraction, expected to start shortly.\nAdditionally, Cytokinetics is developing CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten for the potential treatment of heart failure with preserved ejection fraction (HFpEF). Data from the phase I study support progression to a phase IIa study in patients with HFpEF (initiation expected in the fourth quarter). \nHow Have Estimates Been Moving Since Then?\nIn the past month, investors have witnessed an upward trend in estimates review.\nVGM Scores\nAt this time, Cytokinetics has a poor Growth Score of F, however its Momentum Score is doing a bit better with a D. Charting a somewhat similar path, the stock was allocated a grade of F on the value side, putting it in the lowest quintile for this investment strategy.\nOverall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.\nOutlook\nEstimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Cytokinetics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.\nPerformance of an Industry Player\nCytokinetics belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Insmed (INSM), has gained 5.1% over the past month. More than a month has passed since the company reported results for the quarter ended September 2024.\nInsmed reported revenues of $93.43 million in the last reported quarter, representing a year-over-year change of +18.2%. EPS of -$1.27 for the same period compares with -$1.10 a year ago.\nFor the current quarter, Insmed is expected to post a loss of $1.17 per share, indicating a change of +8.6% from the year-ago quarter. The Zacks Consensus Estimate has changed -0.1% over the last 30 days.\nThe overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Insmed. Also, the stock has a VGM Score of F.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nCytokinetics, Incorporated (CYTK) : Free Stock Analysis Report\nInsmed, Inc. (INSM) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2489251670"}